<code id='AE07F72D17'></code><style id='AE07F72D17'></style>
    • <acronym id='AE07F72D17'></acronym>
      <center id='AE07F72D17'><center id='AE07F72D17'><tfoot id='AE07F72D17'></tfoot></center><abbr id='AE07F72D17'><dir id='AE07F72D17'><tfoot id='AE07F72D17'></tfoot><noframes id='AE07F72D17'>

    • <optgroup id='AE07F72D17'><strike id='AE07F72D17'><sup id='AE07F72D17'></sup></strike><code id='AE07F72D17'></code></optgroup>
        1. <b id='AE07F72D17'><label id='AE07F72D17'><select id='AE07F72D17'><dt id='AE07F72D17'><span id='AE07F72D17'></span></dt></select></label></b><u id='AE07F72D17'></u>
          <i id='AE07F72D17'><strike id='AE07F72D17'><tt id='AE07F72D17'><pre id='AE07F72D17'></pre></tt></strike></i>

          Home / hotspot / comprehensive

          comprehensive


          comprehensive

          author:entertainment    Page View:44148
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In